Hypomagnesemia and proton-pump inhibitors

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 709-716

  Famularo, Giuseppe ^a   Gasbarrone, Laura ^a   Minisola, Giovanni ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Hypomagnesemia; Hypomagnesemic hypoparathyroidism; Magnesium; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; MAGNESIUM ION; OMEPRAZOLE; PANTOPRAZOLE; PARATHYROID HORMONE; PROTON PUMP INHIBITOR; RANITIDINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7;

ACHLORHYDRIA; AUTOSOMAL RECESSIVE DISORDER; DRUG RECHALLENGE; DRUG SAFETY; GENE MUTATION; GENETIC RISK; HEART VENTRICLE ARRHYTHMIA; HETEROZYGOTE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; INTESTINE ABSORPTION; LONG TERM EXPOSURE; MAGNESIUM BLOOD LEVEL; MAGNESIUM METABOLISM; MALABSORPTION; OBSERVATIONAL STUDY; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PHARMACOGENETICS; QT PROLONGATION; RECEPTOR POTENTIAL; REVIEW; STOMACH PH; TETANY; TONIC CLONIC SEIZURE; URINARY EXCRETION;

HUMANS; HYPERCALCIURIA; MAGNESIUM; MAGNESIUM DEFICIENCY; NEPHROCALCINOSIS; PROTON PUMP INHIBITORS; RENAL TUBULAR TRANSPORT, INBORN ERRORS;

EID: 84882952080     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.809062     Document Type: Review

References (47)

1. Forges I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008;336:2-3
2. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012;28:615-20
3. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003;24:47-66
4. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev 2012;70:153-64
5. Wong ET, Rude RK, Singer FR. A high prevalence of hypomagnesemia in hospitalized patients. Am J Clin Pathol 1983;79:348-52
6. Ryzen E. Magnesium homeostasis in critically ill patients. Magnesium 1989;8:201-12
7. Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999;10:1616-22
8. Rondon LJ, Tiel Groenestege WM, Rayssiguier Y, Mazur A. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol 2008;294:R2001-7
9. Chase LR, Slatopolsky E. Secretion and metabolic efficiency of parathyroid hormone in patients with severe hypomagnesemia. J Clin Endocrinol Metab 1974;38:363-71
10. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone and organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf) 1976;5:209-24
11. Freitag JJ, Martin KJ, Conrades MB. Skeletal resistance to parathyroid hormone in magnesium deficiency: studies in isolated perfused bone. J Clin Invest 1974;64:1238-44
12. Thakker RV. Parathyroid disorders and diseases altering calcium metabolism. In: Warrell DA, Cox TM, Firth JD, editors. 5th Edition. Oxford textbook of medicine. Oxford University Press; Oxford; 2010. p. 1850-68
13. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-6
14. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102:2648-54
15. Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ 2008;337:a425
16. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008;69:338-41
17. Broeren MA, Geerdink EA, Vader HL, et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009;151:755-6
18. Doornebal J, Bijlsma R, Brouwer RM. An unknown but potentially serious side effect of proton pump inhibitors: hypomagnesaemia. Ned Tijdschr Geneeskd 2009;153:A711
19. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors: a review. Neth J Med 2009;67:169-72
20. Swaminathan K, Wilson J. Elusive cause of hypomagnesaemia. BMJ 2011;343:d5087
21. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56:112-16
22. Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010;56:168-74
23. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibi-tor therapy: a clinical case series. QJM 2010;103:387-95
24. Fernandez-Fernandez FJ, Sesma P, Cainzos-Romero T, Ferreira-Gonzalez L. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 2010;68:329-30
25. Furlanetto TW, Faulhaber GAM. Hypomagnesemia and proton pump inhibitors. Arch Intern Med 2011;171:1391-2
26. Quasdorff M, Mertens J, Dinter J, Steffen HM. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann Intern Med 2011;155:405-7
27. Matsuyama J, Tsuji K, Doyama H, et al. Hypomagnesemia associated with a proton pump inhibitor. Intern Med 2012;51:2231-4
28. Famularo G, Minisola G, Bravi MC, et al. Tetany, hypomagnesemia and proton-pump inhibitors. Am J Med 2012;125:e7-8
29. Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010;23:194-8
30. Elin RJ. Re-evaluation of the concept of chronic, latent, magnesium deficiency. Magnes Res 2011;24:225-7
31. Leone N, Courbon D, Ducimetiere P, et al. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology 2006;17:308-14
32. Peacock JM, Ohira T, Post W, et al. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010;160:464-70
33. Chiuve SE, Korngold EC, Januzzi JL Jr, et al. Plasma and dietary magnesium and risk of sudden cardiac death in women. Am J Clin Nutr 2011;93:253-60
34. PPI's and hypomagnesemia. Med Lett Drugs Ther 2011;53:25
35. Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012;21:553-9
36. Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2012;9:322-6
37. Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013;83:692-9
38. Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int 2013;83:553-6
39. Kawamura Y. Drugs affecting serum magnesium concentration. Clin Calcium 2012;22:1211-16
40. Bai JP, Hausman E, Lionberger R, Zhang X. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. Mol Pharm 2012; in press
41. Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998;43:763-9
42. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol 2008;24:230-5
43. Voets T, Nilius B, Hoefs S, et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004;279:19-25
44. Costa A, Tejpar S, Prenen H, Van Cutsem E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol 2011;6:227-33
45. Schlingmann KP, Sassen MC, Weber S, et al. Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol 2005;16:3061-9
46. Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013: In press
47. Koulouridis I, Alfayez M, Tighiouart H, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 2013: In press